Viking Therapeutics Completes Enrollment in VK2735 Trial
Completion of Enrollment in Phase 2 VENTURE Trial for VK2735
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, has recently announced the successful completion of enrollment in its Phase 2 VENTURE-Trial investigating the oral tablet formulation of VK2735, which targets obesity. This crucial study focuses on the safety and efficacy of VK2735, a dual agonist for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
The 13-Week Study Overview
The Phase 2 VENTURE-Oral Dosing Trial is designed as a randomized, double-blind, placebo-controlled multicenter study. It aims to assess the safety, tolerability, and pharmacokinetics of VK2735, which is dosed once daily for a period of 13 weeks. The study enrolled approximately 280 adults classified as obese, having a body mass index (BMI) of 30 kg/m2 or higher, or overweight individuals with a BMI of 27 kg/m2 who also have at least one weight-related comorbidity. Participants are randomly assigned to one of the six dosing arms or a placebo for controlled comparison.
Research Objectives and Expectations
The primary objective of the study is to measure the percent change in body weight from the baseline after the 13-week treatment duration. Additionally, secondary and exploratory end points will assess various safety and efficacy measures to gather thorough insights into VK2735's effects.
Dr. Brian Lian, the CEO of Viking Therapeutics, commented on the notable interest in this trial, stating that the enrollment was achieved efficiently due to high enthusiasm for innovative obesity therapeutics. Viking Therapeutics looks forward to releasing data from this trial in the latter half of 2025.
Previous Results from VK2735 Trials
Earlier, Viking had reported encouraging outcomes from a 28-day Phase 1 multiple ascending dose (MAD) trial conducted on healthy volunteers with a BMI of 30 or more. Results from this trial indicated dose-dependent mean body weight reductions, with results up to 8.2%. Moreover, significant weight loss effects were recorded at follow-up visits, highlighting sustained weight reductions even weeks post-treatment.
Additionally, the MAD trial noted that 100% of VK2735-treated participants achieved at least 5% weight loss compared to none in the placebo group, demonstrating the potential effectiveness of VK2735.
Safety Profile and Future Directions
Safety evaluations from the MAD trial depicted that almost all treatment-emergent adverse events were mild or moderate, with the majority reported as mild. The gastrointestinal side effects observed were also predominantly mild, which enhances the drug's acceptability.
As Viking Therapeutics continues with the oral formulation of VK2735, it is also advancing subcutaneous variants through clinical trials. The Phase 2 VENTURE study of VK2735 administered via subcutaneous delivery previously showcased promising data, achieving all primary and secondary trial endpoints with significant weight loss results.
Understanding GLP-1 and Dual Agonists
Glucagon-like peptide-1 (GLP-1) agonists have been pivotal in managing conditions like type 2 diabetes and obesity by improving glucose control, reducing appetite, and enhancing insulin sensitivity. VK2735’s dual-action mechanism, which also activates GIP receptors, may lead to improved therapeutic benefits, extending the potential range of treatment options for patients facing metabolic disorders.
About Viking Therapeutics, Inc.
Viking Therapeutics is committed to developing innovative first-in-class or best-in-class therapies addressing critical unmet needs in metabolic and endocrine disorders. Its pipeline showcases continuing advancements, with several compounds in various clinical trial stages, including VK2735 for obesity and related conditions. The company's ongoing commitment to research demonstrates its ambition to enhance patient health outcomes.
Frequently Asked Questions
What is the main focus of the Phase 2 VENTURE trial?
The Phase 2 VENTURE trial mainly focuses on evaluating the safety and efficacy of VK2735 in treating obesity.
How many participants were enrolled in the study?
Approximately 280 adults were enrolled, targeting those who are obese or overweight with weight-related co-morbidities.
What are the expected outcomes from the study?
The primary expected outcome is the percent change in body weight from the baseline after 13 weeks of treatment.
What safety profile has VK2735 demonstrated?
VK2735 has shown a favorable safety profile, with most adverse events reported as mild or moderate in previous studies.
What is Viking Therapeutics' vision?
Viking Therapeutics aims to develop novel therapies to improve lives significantly for patients suffering from metabolic and endocrine disorders.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
